Literature DB >> 25821031

Glottic and supraglottic pT3 squamous cell carcinoma: outcomes with transoral laser microsurgery.

Dimitrios Pantazis1, Georgia Liapi, Dimitrios Kostarelos, Georgios Kyriazis, Theodoros-Leonidas Pantazis, Maria Riga.   

Abstract

Patients diagnosed with T3 squamous cell laryngeal carcinomas are nowadays offered either organ-preserving surgical or non-surgical treatment, with the optimum approach remaining undefined. No direct comparison of organ-preserving therapeutical options, stratified by anatomical subsites is available in the literature. The aim of this study is to present institutional treatment outcomes for laser-assisted microsurgery (TLM) of laryngeal T3 squamous cell carcinomas and review the relevant literature. Sixty-four consecutive, previously untreated patients were evaluated. Twenty-four supraglottic and 19 glottic patients were treated with TLM and neck dissection, tumor exposure and postoperative upstaging of the tumors through pathology evaluation of the specimens being the only exclusion criteria. Five-year disease-specific survival and organ preservation rates for supraglottic carcinomas were both 91.7 %. The respective values for glottic carcinomas were 63.2 and 73.3 %. TLM-treated T3 supraglottic tumors seem to attribute better outcomes than T3 glottic tumors in terms of recurrence-free survival, organ preservation and local control (p = 0.01, <0.0001 and 0.01, respectively). The results of this study suggest that TLM-treated T3 supraglottic tumors have a good prognosis, substantially better than that of glottic tumors. A literature review, on the other hand, attributes to chemo-radiation-treated T3 supraglottic tumors a considerably poorer prognosis. Further studies of homogenous populations in terms of anatomical subsites are needed in order to reach a consensus regarding treatment of T3 laryngeal tumors.

Entities:  

Mesh:

Year:  2015        PMID: 25821031     DOI: 10.1007/s00405-015-3611-z

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  42 in total

1.  Local control of T3N0 glottic carcinoma by 60 Gy given over five weeks in 2.4 Gy daily fractions. One more point on the biological effective dose (BED) curve.

Authors:  S M Jackson; J H Hay; A D Flores
Journal:  Radiother Oncol       Date:  2001-05       Impact factor: 6.280

2.  Transoral laser microsurgery in treatment of pT2 and pT3 glottic laryngeal squamous cell carcinoma - results of 391 patients.

Authors:  Martin Canis; Alexios Martin; Friedrich Ihler; Hendrik A Wolff; Martina Kron; Christoph Matthias; Wolfgang Steiner
Journal:  Head Neck       Date:  2013-09-02       Impact factor: 3.147

3.  MRI in evaluation of neoplastic invasion into preepiglottic and paraglottic space.

Authors:  Bojan Banko; Vojko Djukic; Jovica Milovanovic; Jelena Kovac; Zorica Novakovic; Ruzica Maksimovic
Journal:  Auris Nasus Larynx       Date:  2014-03-11       Impact factor: 1.863

Review 4.  Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence?

Authors:  Jacques Bernier; Jay S Cooper
Journal:  Oncologist       Date:  2005-03

5.  Comparative estimation of cure rates for supraglottic and glottic cancer in radiotherapy.

Authors:  M Goleń; K Składowski; B Maciejewski
Journal:  Neoplasma       Date:  1999       Impact factor: 2.575

6.  Treatment decisions in T3N0M0 glottic carcinoma.

Authors:  G P Bryant; M G Poulsen; L Tripcony; G J Dickie
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-01-15       Impact factor: 7.038

7.  Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1981-10-22       Impact factor: 91.245

Review 8.  T3-4 squamous cell carcinoma of the larynx treated with radiation therapy alone.

Authors:  W M Mendenhall
Journal:  Semin Radiat Oncol       Date:  1998-10       Impact factor: 5.934

9.  Prognostic factors in T3,N0-1 glottic and transglottic carcinoma. A multifactorial study of 221 cases treated by surgery or radiotherapy.

Authors:  L P Kowalski; M B Batista; C R Santos; A Scopel; J V Salvajolli; H Torloni
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1996-01

10.  Factors predictive of survival in advanced laryngeal cancer.

Authors:  Amy Y Chen; Michael Halpern
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2007-12
View more
  6 in total

Review 1.  Functional outcomes after supracricoid laryngectomy: what do we not know and what do we need to know?

Authors:  Antonio Schindler; Nicole Pizzorni; Francesco Mozzanica; Marco Fantini; Daniela Ginocchio; Andy Bertolin; Erika Crosetti; Giovanni Succo
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-11-06       Impact factor: 2.503

2.  [The value of supracricoid partial laryngectomy in moderately advanced laryngeal cancer (T3-T4a)].

Authors:  U Schroeder; B Wollenberg; K L Bruchhage
Journal:  HNO       Date:  2015-11       Impact factor: 1.284

Review 3.  Evidence and evidence gaps of laryngeal cancer surgery.

Authors:  Susanne Wiegand
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

4.  Comparison of Treatment Outcomes for T3 Glottic Squamous Cell Carcinoma: A Meta-Analysis.

Authors:  Bo Hae Kim; Sung Joon Park; Woo-Jin Jeong; Soon-Hyun Ahn
Journal:  Clin Exp Otorhinolaryngol       Date:  2018-02-22       Impact factor: 3.372

5.  Three-Dimensional Map of Isoprognostic Zones in Glottic Cancer Treated by Transoral Laser Microsurgery as a Unimodal Treatment Strategy.

Authors:  Cesare Piazza; Marta Filauro; Alberto Paderno; Filippo Marchi; Pietro Perotti; Riccardo Morello; Stefano Taboni; Giampiero Parrinello; Fabiola Incandela; Andrea Iandelli; Francesco Missale; Giorgio Peretti
Journal:  Front Oncol       Date:  2018-05-22       Impact factor: 6.244

6.  Transoral Laser Microsurgery for Supraglottic Cancer.

Authors:  Petra Ambrosch; Mireia Gonzalez-Donate; Asita Fazel; Claudia Schmalz; Jürgen Hedderich
Journal:  Front Oncol       Date:  2018-05-09       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.